+

WO1999056666A8 - Traitement des troubles de la sexualite chez certains groupes de patients - Google Patents

Traitement des troubles de la sexualite chez certains groupes de patients

Info

Publication number
WO1999056666A8
WO1999056666A8 PCT/US1999/009610 US9909610W WO9956666A8 WO 1999056666 A8 WO1999056666 A8 WO 1999056666A8 US 9909610 W US9909610 W US 9909610W WO 9956666 A8 WO9956666 A8 WO 9956666A8
Authority
WO
WIPO (PCT)
Prior art keywords
sexual dysfunction
patient groups
treatment
certain patient
methods
Prior art date
Application number
PCT/US1999/009610
Other languages
English (en)
Other versions
WO1999056666A1 (fr
Original Assignee
Rt Alamo Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/071,457 external-priority patent/US6110489A/en
Priority claimed from US09/166,703 external-priority patent/US6194433B1/en
Priority claimed from US09/175,395 external-priority patent/US6132753A/en
Priority claimed from US09/260,099 external-priority patent/US6132757A/en
Priority claimed from US09/262,715 external-priority patent/US6187790B1/en
Priority to JP2000599185A priority Critical patent/JP2002537231A/ja
Priority to AU37806/99A priority patent/AU3780699A/en
Priority to EP99920266A priority patent/EP1079764A4/fr
Priority to CA002319542A priority patent/CA2319542C/fr
Application filed by Rt Alamo Ventures Inc filed Critical Rt Alamo Ventures Inc
Priority to BR9908716-2A priority patent/BR9908716A/pt
Priority to MXPA00010254A priority patent/MXPA00010254A/es
Publication of WO1999056666A1 publication Critical patent/WO1999056666A1/fr
Publication of WO1999056666A8 publication Critical patent/WO1999056666A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)

Abstract

L'invention concerne des procédés de traitement des troubles de la sexualité chez certains groupes de patients. Ces procédés consistent à administrer des compositions pharmaceutiques à des patients ne présentant pas de maladie cardiaque et/ou auxquels on n'a pas administré de nitrates organiques.
PCT/US1999/009610 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients WO1999056666A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MXPA00010254A MXPA00010254A (es) 1998-05-01 1999-04-30 Tratamiento de disfuncion sexual en ciertos grupos de pacientes.
BR9908716-2A BR9908716A (pt) 1998-05-01 1999-04-30 Tratamento de disfunção sexual em certos grupos de pacientes
JP2000599185A JP2002537231A (ja) 1998-05-01 1999-04-30 特定の患者群における性的機能障害の治療
CA002319542A CA2319542C (fr) 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients
EP99920266A EP1079764A4 (fr) 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients
AU37806/99A AU3780699A (en) 1998-05-01 1999-04-30 The treatment of sexual dysfunction in certain patient groups

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US09/071,457 US6110489A (en) 1998-05-01 1998-05-01 Use of quinolines and quinolones to treat male erectile dysfunction
US09/166,703 US6194433B1 (en) 1998-10-05 1998-10-05 Sexual dysfunction in females
US09/175,395 US6132753A (en) 1998-05-01 1998-10-19 Treatment of sexual dysfunction in certain patient groups
US09/260,099 US6132757A (en) 1998-05-01 1999-03-02 Treatment of sexual dysfunction in certain patient groups
US09/262,715 US6187790B1 (en) 1999-03-04 1999-03-04 Use of cilostazol for treatment of sexual dysfunction
US09/260,099 1999-03-04
US09/262,715 1999-03-04
US09/166,703 1999-03-04
US09/175,395 1999-03-04
US09/071,457 1999-03-04

Publications (2)

Publication Number Publication Date
WO1999056666A1 WO1999056666A1 (fr) 1999-11-11
WO1999056666A8 true WO1999056666A8 (fr) 2000-08-10

Family

ID=27535884

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/009610 WO1999056666A1 (fr) 1998-05-01 1999-04-30 Traitement des troubles de la sexualite chez certains groupes de patients

Country Status (7)

Country Link
EP (1) EP1079764A4 (fr)
JP (1) JP2002537231A (fr)
AU (1) AU3780699A (fr)
BR (1) BR9908716A (fr)
CA (1) CA2319542C (fr)
MX (1) MXPA00010254A (fr)
WO (1) WO1999056666A1 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548490B1 (en) 1997-10-28 2003-04-15 Vivus, Inc. Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
US6403597B1 (en) 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6541487B1 (en) 1998-05-01 2003-04-01 R.T. Alamo Ventures I, Llc PDE III inhibitors for treating sexual dysfunction
CA2435876A1 (fr) * 2001-01-26 2002-08-01 R.T. Alamo Ventures I, Llc Traitement de troubles sexuels et de maladie cardio-vasculaire avec des enantiomeres quinolinone
US6727262B2 (en) 2002-03-01 2004-04-27 R.T. Alamo Ventures I, Llc Dichlorinated heterocyclic compounds and methods of synthesis
US6767914B2 (en) 2002-03-01 2004-07-27 R.T. Alamo Ventures I, Llc Fluorinated heterocyclic compounds and methods of synthesis
US6730790B2 (en) 2002-03-01 2004-05-04 R.T. Alamo Ventures I. Llc Chlorinated heterocyclic compounds and methods of synthesis
US7041677B2 (en) 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
GB0208704D0 (en) * 2002-04-16 2002-05-29 Futura Medical Dev Ltd Condom
TWI323660B (en) * 2003-02-25 2010-04-21 Otsuka Pharma Co Ltd Pten inhibitor or maxi-k channels opener
TWI338583B (en) 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
EP0651640A1 (fr) * 1992-07-21 1995-05-10 Knoll AG Utilisation de 7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone dans le traitement de l'angine de poitrine
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
JP2002522388A (ja) * 1998-08-03 2002-07-23 ビーエーエスエフ コーポレーション 性機能障害の治療のためのピリジノン

Also Published As

Publication number Publication date
CA2319542C (fr) 2005-07-12
CA2319542A1 (fr) 1999-11-11
WO1999056666A1 (fr) 1999-11-11
MXPA00010254A (es) 2002-08-06
BR9908716A (pt) 2000-11-21
AU3780699A (en) 1999-11-23
JP2002537231A (ja) 2002-11-05
EP1079764A4 (fr) 2001-09-12
EP1079764A1 (fr) 2001-03-07

Similar Documents

Publication Publication Date Title
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
WO2004019884A3 (fr) Agents et procedes pour stimuler la formation osseuse
WO2005027842A8 (fr) Associations de medicaments destinees au traitement de tumeurs
WO2002041837A3 (fr) Traitement de mucosite
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
NZ332720A (en) Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia
WO2004031129A3 (fr) Nouveaux composes destines au traitement des maladies auto-immunes, des maladies immuno-allergiques et des rejets en cas de greffes d'organes ou de tissus
CA2373794A1 (fr) Compositions et utilisation d'et743 pour le traitement du cancer
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
WO1999056666A8 (fr) Traitement des troubles de la sexualite chez certains groupes de patients
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
EP0281070A3 (fr) Composé pharmaceutique pour le traitement du cancer
WO2001045715A3 (fr) Formulations d'agonistes d'adenosine a1
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
MXPA02000680A (es) Polipeptidos vgf y metodos para tratar desordenes relacionados con vgf.
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses
WO1999065475A3 (fr) Combinaison de phentolamine et apomorphine pour le traitement concernant les fonctions et les dysfonctionnements sexuels
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
MA26648A1 (fr) Associations thérapeutiques pour le traitement de maladies osseuses, et procédé pour leur préparation.
WO2000078800A3 (fr) Compositions combinant la proteine de liaison de decorine et la proteine de surface externe et procedes correspondants
NO984196L (no) FremgangsmÕte for behandling av stoffmisbruk
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин
AU2002300509A1 (en) The Treatment of Sexual Dysfunction in Certain Patient Groups
EA200001091A1 (ru) Способ лечения заболеваний, связанных с образованием конкрементов
UA36490A (uk) Спосіб лікування гнійно-септичних захворювань м'яких тканин

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 37806/99

Country of ref document: AU

Ref document number: 1999920266

Country of ref document: EP

ENP Entry into the national phase in:

Ref document number: 2319542

Country of ref document: CA

Ref document number: 2319542

Country of ref document: CA

Kind code of ref document: A

AK Designated states

Kind code of ref document: C1

Designated state(s): AU BR CA JP MX

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT. BUL. 45/99 UNDER (81) ADD "BR, JP, MX"; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

ENP Entry into the national phase in:

Ref document number: 2000 599185

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/A/2000/010254

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1999920266

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999920266

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载